PTAB Rejects Amgen's Bid For Humira Patent Reviews
The Patent Trial and Appeal Board on Thursday denied two requests by Amgen for reviews of two AbbVie patents covering the megablockbuster Humira, just months after Amgen had asked the U.S. Food and...To view the full article, register now.
Already a subscriber? Click here to view full article